Daewoong Pharmaceutical Expands AI into Drug Formulation Design with $4 Million Government Project

Daewoong Pharmaceutical is leading a South Korean government-funded project to develop an AI-based platform for drug formulation design, focusing on creating optimal formulations based on desired pharmacokinetic characteristics. The three-and-a-half-year project, funded with approximately KRW 5.3 billion, will see the company collaborate with Kookmin University, Chung-Ang University, and AI pharmaceutical technology company AIJPharm.

The platform aims to shift the formulation development process from experience-based and iterative experimentation to a data-driven approach, using machine learning and Design of Experiments methodologies. Researchers will define desired pharmacokinetic profiles, and the AI system will recommend formulation candidates, excipient combinations, and experimental conditions to achieve those objectives.

A key component of the project is the development of a biorelevant dissolution testing system to simulate gastrointestinal conditions and validate AI predictions, ultimately creating a feedback loop between computational prediction and laboratory experimentation to refine formulation design.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.